

David C Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6924861/publications.pdf>

Version: 2024-02-01

199
papers

33,619
citations

12303

69
h-index

3815

178
g-index

202
all docs

202
docs citations

202
times ranked

38781
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	13.9	10,727
2	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
3	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	0.8	2,015
4	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq0 0 0 rgBT /Overlock Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
5	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	13.7	685
6	Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. <i>Mass Spectrometry Reviews</i> , 2005, 24, 661-700.	2.8	683
7	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1675-1684.	0.8	584
8	Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. <i>Science Translational Medicine</i> , 2011, 3, 111ra121.	5.8	531
9	Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 412-419.	0.8	405
10	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	3.4	388
11	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	0.8	385
12	Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/Neu-Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 2218-2224.	0.8	355
13	Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. <i>Kidney International</i> , 1997, 52, 223-228.	2.6	328
14	A longitudinal study of ammonia, acetone and propanol in the exhaled breath of 30 subjects using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006, 27, 321-337.	1.2	323
15	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017, 7, 620-629.	7.7	321
16	Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 4202-4208.	0.8	300
17	Progress in SIFT-MS: Breath analysis and other applications. <i>Mass Spectrometry Reviews</i> , 2011, 30, 236-267.	2.8	289
18	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 850-858.	0.8	288

#	ARTICLE	IF	CITATIONS
19	Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. <i>Cancer</i> , 2007, 110, 2809-2818.	2.0	283
20	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	0.8	267
21	American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 3388-3404.	0.8	246
22	Time variation of ammonia, acetone, isoprene and ethanol in breath: a quantitative SIFT-MS study over 30 days. <i>Physiological Measurement</i> , 2003, 24, 107-119.	1.2	210
23	Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. <i>Urology</i> , 1999, 53, 260-266.	0.5	199
24	Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2527-2533.	0.8	198
25	Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. <i>Cancer</i> , 2008, 113, 975-984.	2.0	192
26	Multi-Institutional Randomized Phase II Trial of the Etoposide Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1439-1446.	0.8	188
27	Living With Prostate Cancer: Patients' and Spouses' Psychosocial Status and Quality of Life. <i>Journal of Clinical Oncology</i> , 2007, 25, 4171-4177.	0.8	188
28	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1529-1554.	2.3	174
29	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169
30	Analysis of formaldehyde in the headspace of urine from bladder and prostate cancer patients using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1999, 13, 1354-1359.	0.7	166
31	A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. <i>Urology</i> , 1998, 52, 257-260.	0.5	164
32	Trace gases in breath of healthy volunteers when fasting and after a protein-calorie meal: a preliminary study. <i>Journal of Applied Physiology</i> , 1999, 87, 1584-1588.	1.2	160
33	Small-molecule SMAC mimetics as new cancer therapeutics. , 2014, 144, 82-95.		160
34	Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 1664-1664.	0.8	158
35	The Novel Selected-ion Flow Tube Approach to Trace Gas Analysis of Air and Breath. , 1996, 10, 1183-1198.		154
36	A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 7490-7497.	3.2	148

#	ARTICLE	IF	CITATIONS
37	Advances in Prostate Cancer Chemotherapy: A New Era Begins. <i>Ca-A Cancer Journal for Clinicians</i> , 2005, 55, 300-318.	157.7	146
38	Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2013, 18, 163-173.	1.9	145
39	Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995, 1, 195-198.	0.8	141
40	A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6295-6303.	3.2	138
41	Quantification of acetaldehyde released by lung cancer cells in vitrousing selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 845-850.	0.7	137
42	Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Tj ETQq0 0 0 rgBT /Overlock 10 T	2.9	134
43	Analysis of breath, exhaled via the mouth and nose, and the air in the oral cavity. <i>Journal of Breath Research</i> , 2008, 2, 037013.	1.5	133
44	A longitudinal study of breath isoprene in healthy volunteers using selected ion flow tube mass spectrometry (SIFT-MS). <i>Physiological Measurement</i> , 2006, 27, 13-22.	1.2	131
45	Application of ion chemistry and the SIFT technique to the quantitative analysis of trace gases in air and on breath. <i>International Reviews in Physical Chemistry</i> , 1996, 15, 231-271.	0.9	130
46	A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. <i>Physiological Measurement</i> , 2006, 27, 637-648.	1.2	122
47	Selected ion flow tube - mass spectrometry: detection and real-time monitoring of flavours released by food products. <i>Rapid Communications in Mass Spectrometry</i> , 1999, 13, 585-596.	0.7	120
48	SIFT studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with a series of volatile carboxylic acids and esters. <i>International Journal of Mass Spectrometry and Ion Processes</i> , 1998, 172, 137-147.	1.9	118
49	Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma. <i>Cancer</i> , 2009, 115, 4110-4117.	2.0	117
50	An exploratory comparative study of volatile compounds in exhaled breath and emitted by skin using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 526-532.	0.7	116
51	Reactions of Hydrated Hydronium Ions and Hydrated Hydroxide Ions with Some Hydrocarbons and Oxygen-Bearing Organic Molecules. <i>The Journal of Physical Chemistry</i> , 1995, 99, 15551-15556.	2.9	111
52	Volatile metabolites in the exhaled breath of healthy volunteers: their levels and distributions. <i>Journal of Breath Research</i> , 2007, 1, 014004.	1.5	110
53	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3391-3399.	0.8	110
54	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , 2003, 61, 774-780.	0.5	106

#	ARTICLE	IF	CITATIONS
55	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014, 120, 2684-2693.	2.0	105
56	Ambient analysis of trace compounds in gaseous media by SIFT-MS. <i>Analyst</i> , The, 2011, 136, 2009.	1.7	104
57	Direct, rapid quantitative analyses of BVOCs using SIFT-MS and PTR-MS obviating sample collection. <i>TrAC - Trends in Analytical Chemistry</i> , 2011, 30, 945-959.	5.8	98
58	A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. <i>Urology</i> , 1997, 50, 401-407.	0.5	92
59	Enhancement of 1,25-Dihydroxyvitamin D3-Mediated Antitumor Activity With Dexamethasone. <i>Journal of the National Cancer Institute</i> , 1998, 90, 134-141.	3.0	92
60	Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014, 120, 692-701.	2.0	91
61	A selected ion flow tube mass spectrometry study of ammonia in mouth and nose exhaled breath and in the oral cavity. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 783-789.	0.7	88
62	Acetone, ammonia and hydrogen cyanide in exhaled breath of several volunteers aged 4-83 years. <i>Journal of Breath Research</i> , 2007, 1, 011001.	1.5	83
63	Quantification of breath isoprene using the selected ion flow tube mass spectrometric analytical method. , 1999, 13, 1733-1738.		81
64	Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 2540-2545.	0.8	79
65	On-line measurement of the absolute humidity of air, breath and liquid headspace samples by selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2001, 15, 563-569.	0.7	78
66	On-line, simultaneous quantification of ethanol, some metabolites and water vapour in breath following the ingestion of alcohol. <i>Physiological Measurement</i> , 2002, 23, 477-489.	1.2	78
67	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with several amines and some other nitrogen-containing molecules. <i>International Journal of Mass Spectrometry</i> , 1998, 176, 203-211.	0.7	76
68	A new "online"™ method to measure increased exhaled isoprene in end-stage renal failure. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 836-839.	0.4	75
69	Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design. <i>Clinical Genitourinary Cancer</i> , 2006, 4, 299-302.	0.9	73
70	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2012, 30, 749-757.	1.2	72
71	Influence of water vapour on selected ion flow tube mass spectrometric analyses of trace gases in humid air and breath. <i>Rapid Communications in Mass Spectrometry</i> , 2000, 14, 1898-1906.	0.7	70
72	A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219). <i>Journal of Urology</i> , 2009, 181, 2476-2481.	0.2	69

#	ARTICLE	IF	CITATIONS
73	Characterization of Bone Metastases from Rapid Autopsies of Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3924-3932.	3.2	69
74	Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). <i>Investigational New Drugs</i> , 2005, 23, 79-84.	1.2	68
75	Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer. <i>Oncology</i> , 2006, 71, 168-175.	0.9	68
76	Concurrent use of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ precursor ions for the detection and quantification of diverse trace gases in the presence of air and breath by selected ion-flow tube mass spectrometry. <i>International Journal of Mass Spectrometry</i> , 2001, 209, 81-97.	0.7	66
77	Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 249-257.	1.2	66
78	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 155-162.	1.1	66
79	COMBINATION CISPLATIN, 5-FLUOROURACIL AND RADIATION THERAPY FOR LOCALLY ADVANCED UNRESECTABLE OR MEDICALLY UNFIT BLADDER CANCER CASES: A SOUTHWEST ONCOLOGY GROUP STUDY. <i>Journal of Urology</i> , 2001, 165, 56-61.	0.2	65
80	Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 511-517.	0.4	65
81	Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. <i>Bioanalysis</i> , 2014, 6, 843-857.	0.6	65
82	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 525-533.	3.4	65
83	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	0.8	65
84	Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 296-304.	1.3	64
85	Genetic counterselective procedure to isolate interspecific cell hybrids containing single human chromosomes: Construction of cell hybrids and recombinant DNA libraries specific for human chromosomes 3 and 4. <i>Somatic Cell and Molecular Genetics</i> , 1986, 12, 163-174.	0.7	63
86	Reactions of H ₃ O ⁺ and OH [•] ions with some organic molecules; applications to trace gas analysis in air. <i>International Journal of Mass Spectrometry and Ion Processes</i> , 1995, 145, 177-186.	1.9	62
87	Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 125, 28-37.	2.9	62
88	Selected ion flow tube mass spectrometry of urine headspace. , 1999, 13, 724-729.		60
89	Quantitative selected ion flow tube mass spectrometry: The influence of ionic diffusion and mass discrimination. <i>Journal of the American Society for Mass Spectrometry</i> , 2001, 12, 863-872.	1.2	60
90	A selected ion flow tube (SIFT), study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of alkenes; in support of SIFT-MS. <i>International Journal of Mass Spectrometry</i> , 2002, 218, 87-101.	0.7	59

#	ARTICLE	IF	CITATIONS
91	A phase II trial of all- trans -retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 349-356.	1.1	58
92	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020, 123, 1590-1598.	2.9	57
93	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476.	0.9	56
94	Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder. <i>Journal of Urology</i> , 2008, 180, 2384-2388.	0.2	54
95	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 1247-1257.	3.2	54
96	Selected ion flow tube studies of the reactions of H3O+, NO+, and O2+ with several aromatic and aliphatic monosubstituted halocarbons. <i>International Journal of Mass Spectrometry</i> , 1999, 189, 213-223.	0.7	53
97	Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 851-859.	1.1	53
98	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 297-306.	1.2	51
99	A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 461-472.	1.2	51
100	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. <i>Investigational New Drugs</i> , 2011, 29, 1432-1440.	1.2	49
101	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3002-3002.	0.8	47
102	Analysis of petrol and diesel vapour and vehicle engine exhaust gases using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2002, 16, 1124-1134.	0.7	46
103	The concentration distributions of some metabolites in the exhaled breath of young adults. <i>Journal of Breath Research</i> , 2007, 1, 026001.	1.5	46
104	Quantification of volatile metabolites in exhaled breath by selected ion flow tube mass spectrometry, SIFT-MS. <i>Clinical Mass Spectrometry</i> , 2020, 16, 18-24.	1.9	46
105	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	0.8	45
106	Increase of acetone and ammonia in urine headspace and breath during ovulation quantified using selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2003, 24, 191-199.	1.2	44
107	Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscleâ€invasive bladder cancer. <i>Cancer</i> , 2012, 118, 44-53.	2.0	44
108	The Selected Ion Flow Tube Method for Workplace Analyses of Trace Gases in Air and Breath: Its Scope, Validation, and Applications. <i>Journal of Occupational and Environmental Hygiene</i> , 1998, 13, 817-823.	0.5	42

#	ARTICLE	IF	CITATIONS
109	A selected ion flow tube study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with some phenols, phenyl alcohols and cyclic carbonyl compounds in support of SIFT-MS and PTR-MS. <i>International Journal of Mass Spectrometry</i> , 2004, 239, 139-146.	0.7	42
110	Generation of volatile compounds on mouth exposure to urea and sucrose: implications for exhaled breath analysis. <i>Physiological Measurement</i> , 2006, 27, N7-N17.	1.2	42
111	Volatile compounds in health and disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011, 14, 455-460.	1.3	40
112	Population pharmacokinetics of hydroxyurea in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 417-422.	1.1	38
113	Quantification of volatile compounds in the headspace of aqueous liquids using selected ion flow tube mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2002, 16, 2148-2153.	0.7	38
114	SIFT-MS and FA-MS methods for ambient gas phase analysis: developments and applications in the UK. <i>Analyst</i> , 2015, 140, 2573-2591.	1.7	38
115	Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium. <i>Journal of Clinical Oncology</i> , 2009, 27, 2772-2778.	0.8	36
116	Expression of Nuclear Antigen Ki-67 in Prostate Cancer Needle Biopsy and Radical Prostatectomy Specimens. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1941-1942.	3.0	35
117	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. <i>Cancer</i> , 2003, 98, 1603-1610.	2.0	35
118	Association between Agent Orange and prostate cancer: a pilot case-control study. <i>Urology</i> , 2004, 63, 757-760.	0.5	35
119	Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. <i>Urology</i> , 2004, 64, 69-73.	0.5	35
120	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015, 33, 652-663.	1.2	35
121	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. <i>European Urology</i> , 2015, 67, 310-318.	0.9	35
122	Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2003, 98, 269-276.	2.0	34
123	Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Maintenance Sunitinib Versus Placebo After Chemotherapy for Patients with Advanced Urothelial Carcinoma: Scientific Rationale and Study Design. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 460-463.	0.9	33
124	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018, 16, 643-654.	1.5	33
125	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1421-1429.	1.2	33
126	A selected ion flow tube, SIFT, study of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ ions with a series of diols. <i>International Journal of Mass Spectrometry</i> , 2002, 218, 227-236.	0.7	32

#	ARTICLE	IF	CITATIONS
127	Megestrol Acetate in the Treatment of Hormone Refractory Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 308-310.	0.6	32
128	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ , and O ₂ ⁺ with eleven amine structural isomers of c ₅ h ₁₃ n. International Journal of Mass Spectrometry, 1999, 185-187, 139-147.	0.7	30
129	A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder. Urology, 2013, 82, 111-117.	0.5	30
130	What is the real utility of breath ammonia concentration measurements in medicine and physiology?. Journal of Breath Research, 2018, 12, 027102.	1.5	30
131	A SIFT study of the reactions of H ₂ ONO ⁺ ions with several types of organic molecules. International Journal of Mass Spectrometry, 2003, 230, 1-9.	0.7	29
132	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Investigational New Drugs, 2014, 32, 1005-1016.	1.2	29
133	CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. Urologic Clinics of North America, 1999, 26, 323-331.	0.8	28
134	Kinetics and isotope patterns of ethanol and acetaldehyde emissions from yeast fermentations of glucose and glucose-6,6-d ₂ using selected ion flow tube mass spectrometry: a case study. Rapid Communications in Mass Spectrometry, 2002, 16, 69-76.	0.7	28
135	Course of distress and quality of life in testicular cancer patients before, during, and after chemotherapy: Results of a pilot study. Psycho-Oncology, 2003, 12, 814-820.	1.0	28
136	The quantification of carbon dioxide in humid air and exhaled breath by selected ion flow tube mass spectrometry. Rapid Communications in Mass Spectrometry, 2009, 23, 1419-1425.	0.7	28
137	A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. European Journal of Cancer, 2017, 83, 229-236.	1.3	28
138	All- trans -retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. Cancer Chemotherapy and Pharmacology, 1997, 41, 133-139.	1.1	26
139	On-line analysis of diesel engine exhaust gases by selected ion flow tube mass spectrometry. Rapid Communications in Mass Spectrometry, 2004, 18, 2830-2838.	0.7	26
140	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 1994, 33, 347-354.	1.1	25
141	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia, 2016, 18, 1-9.	2.3	25
142	Phase II trial of suramin in patients with metastatic renal cell carcinoma. Investigational New Drugs, 1999, 17, 183-186.	1.2	24
143	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemotherapy and Pharmacology, 2013, 72, 1089-1096.	1.1	24
144	Account: On the Features, Successes and Challenges of Selected Ion Flow Tube Mass Spectrometry. European Journal of Mass Spectrometry, 2013, 19, 225-246.	0.5	23

#	ARTICLE	IF	CITATIONS
145	Treatment of Biochemical Recurrence of Prostate Cancer With Granulocyte-Macrophage Colony-Stimulating Factor Secreting, Allogeneic, Cellular Immunotherapy. <i>Journal of Urology</i> , 2008, 180, 2011-2018.	0.2	22
146	Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 105-111.	0.5	21
147	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	0.9	21
148	An investigation of the reactions of H ₃ O ⁺ and O ₂ ⁺ with NO, NO ₂ , N ₂ O and HNO ₂ in support of selected ion flow tube mass spectrometry. , 2000, 14, 646-651.		20
149	Selected ion flow tube studies of the reactions of H ₃ O ⁺ , NO ⁺ and O ₂ ⁺ with the anaesthetic gases halothane, isoflurane and sevoflurane. <i>Rapid Communications in Mass Spectrometry</i> , 2002, 16, 1860-1870.	0.7	20
150	A new concept in cancer care: The supportive care program. <i>American Journal of Hospice and Palliative Medicine</i> , 1999, 16, 713-722.	0.8	19
151	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 65-68.	1.1	18
152	Adjuvant and neoadjuvant therapy in prostate cancer. <i>Seminars in Oncology</i> , 2001, 28, 3-12.	0.8	18
153	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. <i>Journal of Clinical Oncology</i> , 2018, 36, 617-623.	0.8	18
154	A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 777-784.	1.1	17
155	On the importance of accurate quantification of individual volatile metabolites in exhaled breath. <i>Journal of Breath Research</i> , 2017, 11, 047106.	1.5	17
156	Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3615-3615.	0.8	17
157	Novel gemcitabine-containing triplets in the management of urothelial cancer. <i>Seminars in Oncology</i> , 2002, 29, 20-24.	0.8	16
158	Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy. <i>Cancer</i> , 2011, 117, 2419-2425.	2.0	15
159	Phase I study of MEDI0639 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3024-3024.	0.8	14
160	Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032. <i>Urology</i> , 2011, 77, 1172-1176.	0.5	12
161	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
162	Reagent and analyte ion hydrates in secondary electrospray ionization mass spectrometry (SESI-MS), their equilibrium distributions and dehydration in an ion transfer capillary: Modelling and experiments. <i>Rapid Communications in Mass Spectrometry</i> , 2021, 35, e9047.	0.7	12

#	ARTICLE	IF	CITATIONS
163	THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER. <i>Urologic Clinics of North America</i> , 1997, 24, 433-437.	0.8	11
164	Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 433-441.	1.1	11
165	A phase I trial of high-dose continuous-infusion hydroxyurea. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 139-143.	1.1	10
166	Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma. <i>Cancer</i> , 2006, 106, 1715-1721.	2.0	10
167	Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e592-e601.	0.9	9
168	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2012, 30, 4505-4505.	0.8	9
169	Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 179-185.	1.1	8
170	The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 934-941.	0.4	8
171	The increase of breath ammonia induced by niacin ingestion quantified by selected ion flow tube mass spectrometry. <i>Physiological Measurement</i> , 2006, 27, 437-444.	1.2	8
172	Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 318-322.	0.9	8
173	Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 188-194.	1.2	8
174	Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma. <i>Cancer</i> , 2001, 91, 2175-2180.	2.0	7
175	Recent SIFT-MS Studies of Volatile Compounds in Physiology, Medicine and Cell Biology. , 2013, , 48-76.		7
176	Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 272-276.	1.1	6
177	A phase II trial of CI-958 in patients with hormone-refractory prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 511-517.	1.1	6
178	ORAL CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCER. <i>Urologic Clinics of North America</i> , 1999, 26, 333-340.	0.8	6
179	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. <i>Advances in Radiation Oncology</i> , 2016, 1, 59-66.	0.6	6
180	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>International Journal of Molecular Sciences</i> , 2022, 23, 4.	1.8	6

#	ARTICLE	IF	CITATIONS
181	Chemotherapy for localized, high-risk prostate cancer. <i>Seminars in Radiation Oncology</i> , 2003, 13, 152-157.	1.0	5
182	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 332-339.e2.	0.9	5
183	Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 31, 363-368.	1.1	4
184	Oral Chemotherapy in the Treatment of Hormone-Refractory Prostate Cancer. <i>Drugs</i> , 1999, 58, 127-131.	4.9	4
185	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. <i>Cancer</i> , 2006, 106, 2617-2623.	2.0	4
186	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. <i>Urology</i> , 2022, 167, 171-178.	0.5	4
187	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018, 35, 21.	1.2	3
188	Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 271-280.	1.1	2
189	Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2016, 21, 402.	1.9	2
190	Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for deâ€œplementation. <i>Cancer</i> , 2018, 124, 3971-3974.	2.0	2
191	Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13539-e13539.	0.8	2
192	Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11057-11057.	0.8	2
193	Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 189-199.	1.0	2
194	A phase I trial of high-dose oral tamoxifen and CHOPE. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 65-68.	1.1	1
195	Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 33, 347-354.	1.1	1
196	Academic Cancer Center Phase I Program Development. <i>Oncologist</i> , 2017, 22, 369-374.	1.9	0
197	Targeting C-Met/VEGF in Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , 265-276.	0.0	0
198	Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2531-2531.	0.8	0

#	ARTICLE	IF	CITATIONS
199	ABLE: Phase 2, single-arm, two-stage study of nabpaclitaxel with anti-PD1/PDL1 in advanced urothelial cancer.. Journal of Clinical Oncology, 2022, 40, 502-502.	0.8	0